Clinical trials: Cancer, Bladder
Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer.
- Conditions
- Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT01639521
- Testing
- cisplatin, gemcitabine hydrochloride, methotrexate
- Sponsor
- University of Southern California
Bladder Cancer, Cervical Cancer
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells.
- Conditions
- Bladder Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer
- Trial name
- NCT00002949
- Testing
- paclitaxel, vinorelbine tartrate, radiation therapy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Chicago
Cutaneous Melanoma, Non-small Cell Lung Cancer
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma
- Trial name
- NCT03633110
- Testing
- GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genocea Biosciences, Inc.
Urothelial Carcinoma of the Bladder
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
Purposes are to determine whether various cohorts of bladder cancer patients have detectable tCTC's, determine it tCTC levels vary with the natural history of bladder cancer and to see if tCTC's provide novel information.Study…
- Trial name
- NCT02246738
- Testing
- Blood Collection
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Bladder Cancer, Nerve Sheath Tumor
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody ([89Zr]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid…
- Conditions
- Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies
- Trial name
- NCT07664397
- Testing
- [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Flavell, MD, PhD
Bladder Cancer
The Accuracy of Optic Biopsies Versus Conventional Biopsies for the Diagnosis of Superficial Bladder Neoplasia
This study evaluates the accuracy of Confocal Laser Endomicroscopy (CLE) in the diagnostic of non-invasive flat and exophytic bladder neoplasia. CLE results are compared to histopathology results.
- Trial name
- NCT02841904
- Testing
- Confocal LASER Endomicroscopy
- Where
- Denmark
- Volunteers
- 189 people
- Sponsor
- Herlev Hospital
Superficial Bladder Cancer
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC.
- Trial name
- NCT02773849
- Testing
- ADSTILADRIN
- Where
- 34 sites in United States
- Volunteers
- 157 people
- Sponsor
- Ferring Pharmaceuticals
Non-muscle-invasive Bladder Cancer
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
- Trial name
- NCT05710848
- Testing
- STM-416
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- SURGE Therapeutics
Cancer, Neoadjuvant Therapy
Development and Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer
This study is a multi-center observational study without interventions, including the construction of an AI predictive model, with retrospective and prospective testing.
- Trial name
- NCT06909643
- Testing
- Artificial intelligence (AI)-based predictive model
- Where
- China
- Volunteers
- 469 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hematuria, Acute Cystitis With Hematuria
Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?
This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy workup.
- Conditions
- Hematuria, Acute Cystitis With Hematuria, Bladder Cancer, Urothelial Carcinoma
- Trial name
- BLUSH (NCT07037589)
- Testing
- investigation setting (cystoscopy + CTU + cytology), Cystoscopy - CTU - cytology (if needed)
- Where
- Sweden
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy.
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
Urothelial carcinoma of the bladder mostly is chemically induced and represents the second prevalent urooncological disease. About 20% of newly diagnosed urothelial carcinoma cases of the bladder are already advanced or…
- Trial name
- NCT01265940
- Testing
- Pazopanib as add-on to vinflunine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Prof. Dr. Thomas Otto
Bladder Cancer Recurrence
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine
- Trial name
- NCT00903240
- Where
- 20 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Predictive Biosciences
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers
The goal of this study is to demonstrate a significant gain in sensitivity versus surgical curage (extended pelvic) for initial lymph node staging of late FDG-PET images (2.5 hours) versus standard images (1 hour), analyzed by…
- Trial name
- TARDITEP (NCT06537960)
- Testing
- 18FDG PET-CT
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Hopital Foch
Bladder Cancer
Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors
This study compare the efficacy of conventional photodynamic (PDD) guided transurethral bladder tumor resection in the operating theatre with outpatient PDD guided laser destruction of bladder tumors through flexible cystoscopes.
- Trial name
- LaserIII (NCT02886026)
- Testing
- Bladder tumor resection using diathermia, Diode laser (980 nm) tumor destruction
- Where
- Denmark
- Volunteers
- 248 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Bladder Cancer, Carcinoma, Transitional Cell
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Primary Objective: To analyse time to tumor progression in patients cystectomized for locally advanced transitional cell carcinoma (TCC) of the bladder, who are not suitable for cisplatin-based chemotherapy (i.e.
- Trial name
- NCT00146276
- Testing
- gemcitabine
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Association of Urologic Oncology (AUO)
Bladder Cancer
Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)
Trimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or…
- Trial name
- BLADAPT (NCT07043543)
- Testing
- Adaptive radiotherapy, standard radiotherapy
- Where
- 11 sites in France
- Volunteers
- 120 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Synovial Cell Cancer, Melanoma
Evaluation for NCI Surgery Branch Clinical Research Protocols
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large…
- Conditions
- Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00001823
- Where
- United States
- Volunteers
- 7,000 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Tumor, Magnetic Resonance Imaging
Medical Imaging in Bladder Tumors by MRI
This study prospectively included 178 patients with bladder neoplastic lesions who planned to undergo surgery (with or without preoperative neoadjuvant chemotherapy).
- Trial name
- NCT06033040
- Testing
- MRI
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma, Renal Cell Carcinoma
A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors
Background: Combinations of dendritic and cytokine-induced killer cell (D-CIK) based adoptive immunotherapy and anti-PD-1 antibody may enhance the immune response and stop cancer cells from growing.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02886897
- Testing
- D-CIK and anti-PD-1 antibody
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Bladder Cancer
COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT
Bladder cancer is one of the most common cancers in older adults. The standard treatment for many bladder tumors is a surgical procedure called transurethral resection of bladder tumor (TUR-BT).
- Trial name
- NCT07481123
- Testing
- Subpectineal Obturator Nerve Block, Interfacial Obturator Nerve Block
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Yavuz Saygılı
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.